||Researchers at the University
of Pennsylvania School of Medicine have found
that proteins known to promote cell death are also necessary
for the maturation and proliferation of immune cells.
||The Penn scientists discovered that in
the cells that lack the pro-death proteins Bax and Bak, calcium
signaling is disrupted and energy production is reduced.
Restoration of Bax corrects the signaling problems, increases
energy production, and stimulates cell division.
||The findings bolster the team’s
hypothesis that metabolic cell activity directly controls
life and death decisions in cells.
||The results were published online in
the journal Immunity.
(PHILADELPHIA) – Researchers at the University
of Pennsylvania School of Medicine have found that proteins known to promote cell
death are also necessary for the maturation and proliferation of
immune cells. Activation of T-cell receptors on the surface of
lymphocytes by foreign antigens initiate a calcium-mediated signaling
pathway that ends in cell differentiation and growth. The Penn
scientists discovered that in the cells that lack the pro-death
proteins Bax and Bak, calcium signaling is disrupted and energy
production is reduced. Restoration of Bax corrects the signaling
problems, increases energy production, and stimulates cell
The results, published online in the journal Immunity, bolster the team’s
hypothesis that metabolic cell activity directly controls life and death
decisions in cells. This issue also includes a related commentary by
the study’s lead author, Russell Jones, PhD, and senior author
Craig B. Thompson, MD.
It is well known that cells that lack Bax (Bcl-2-associated X protein)
and Bak (Bcl-2-antagonist/killer) continue living under conditions that
would cause normal cells to undergo programmed cell death or apoptosis.
What is less well understood, is why lymphocytes missing these key proteins
are unable to trigger a strong immune
response and do not proliferate as normal in response to stimulation.
“We simply say they are the same thing,” says Thompson,
Director of the Abramson Cancer Center and Chairman and Professor of
Cancer Biology and Medicine. “The molecular basis of both findings
is based on how Bax and Bak work on intracellular membranes.”
Specifically, the team found that when the T-cell receptor was stimulated
on mutant cells lacking both proteins, proliferation was severely reduced
relative to normal cells. Closer investigation showed that the amount
and rate of calcium release from intracellular stores was altered in
the mutant cells.
The inadequate calcium signals were unable to stimulate the mitochondria,
which are the energy factories in the cell. Without mitochondrial activation,
a key by-product of energy production, called reactive
oxygen species or ROS, were not produced. And because ROS tell the cell to divide, cell
proliferation is compromised.
Although Thompson’s group investigated the function of Bax and
Bak in T cells, the team thinks their findings will likely apply to many
different cell types. When a cell receives signals to increase metabolism,
it increases mitochondrial activity and energy production. That leads
to the production of more energy than the cell can deal with, and consequently,
the release of ROS. “It is the release of reactive oxygen species
by the mitochondria that actually generate the proliferation. We think
that is the basis of all cell proliferation,” says Thompson.
The study was funded by the National
Institutes of Health and the Abramson
Family Cancer Research Institute. Russell Jones received
support from the Cancer
Research Institute and the Canadian
Institutes for Health Research. Co-author Connie
support from the Human
Frontiers Science Program.
Additional co-authors include Thi Bui, Carl White, Muniswamy Madesh,
Connie Krawczyk, Tullia Lindsten, Brian Hawkins, Sara Kubek, Hao Shen,
and J. Kevin Foskett from Penn; Kenneth
Frauwirth from the University
of Maryland; Y.
Lynn Wang from the Weill
Medical College of Cornell University;
Stuart J. Conway, H. Llewelyn Roderick, and Martin D. Bootman from The
The Abramson Cancer Center (ACC) of
the University of Pennsylvania is a national
leader in cancer research, patient care, and education. The
pre-eminent position of the Cancer Center is reflected in
its continuous designation as a Comprehensive Cancer Center
by the National Cancer Institute for 30 years, one of 39
such Centers in the United States. The ACC is dedicated to
innovative and compassionate cancer care. The clinical program,
comprised of a dedicated staff of physicians, nurse practitioners,
nurses, social workers, physical therapists, nutritionists
and patient support specialists, currently sees over 50,000
outpatient visits, 3400 inpatient admissions, and provides
over 25,000 chemotherapy treatments, and more than 65,000
radiation treatments annually. Not only is the ACC dedicated
to providing state-of-the-art cancer care, the latest forms
of cancer prevention, diagnosis, and treatment are available
to our patients through clinical themes that developed in
the relentless pursuit to eliminate the pain and suffering
from cancer. In addition, the ACC is home to the 300 research
scientists who work relentlessly to determine the pathogenesis
of cancer. Together, the faculty is committed to improving
the prevention, diagnosis and treatment of cancer.
PENN Medicine is
a $3.5 billion enterprise dedicated to the related missions
of medical education, biomedical research, and excellence in
patient care. PENN Medicine consists of the University of Pennsylvania
School of Medicine (founded in 1765 as the nation's first medical
school) and the University of Pennsylvania Health System.
Penn's School of Medicine is currently ranked #3 in the
nation in U.S.News & World Report's survey of top research-oriented
medical schools; and, according to most recent data from the
National Institutes of Health, received over $379 million in
NIH research funds in the 2006 fiscal year. Supporting 1,400
fulltime faculty and 700 students, the School of Medicine is
recognized worldwide for its superior education and training
of the next generation of physician-scientists and leaders of
The University of Pennsylvania Health System includes
three hospitals — its flagship hospital,
the Hospital of the University of Pennsylvania, rated one of
the nation’s “Honor Roll” hospitals by U.S.News & World
Report; Pennsylvania Hospital, the nation's first hospital; and
Penn Presbyterian Medical Center — a
faculty practice plan; a primary-care provider network; two multispecialty
satellite facilities; and home care and hospice.
Penn Medicine is one of the world's leading academic medical centers, dedicated to the related missions of medical education, biomedical research, and excellence in patient care. Penn Medicine consists of the Raymond and Ruth Perelman School of Medicine at the University of Pennsylvania (founded in 1765 as the nation's first medical school) and the University of Pennsylvania Health System, which together form a $6.7 billion enterprise.
The Perelman School of Medicine has been ranked among the top five medical schools in the United States for the past 20 years, according to U.S. News & World Report's survey of research-oriented medical schools. The School is consistently among the nation's top recipients of funding from the National Institutes of Health, with $392 million awarded in the 2016 fiscal year.
The University of Pennsylvania Health System's patient care facilities include: The Hospital of the University of Pennsylvania and Penn Presbyterian Medical Center -- which are recognized as one of the nation's top "Honor Roll" hospitals by U.S. News & World Report -- Chester County Hospital; Lancaster General Health; Penn Wissahickon Hospice; and Pennsylvania Hospital -- the nation's first hospital, founded in 1751. Additional affiliated inpatient care facilities and services throughout the Philadelphia region include Good Shepherd Penn Partners, a partnership between Good Shepherd Rehabilitation Network and Penn Medicine.
Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities. In fiscal year 2016, Penn Medicine provided $393 million to benefit our community.